Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Economic Burden of Gastroesophageal Reflux Disease, Barrett's Esophagus, and Esophageal Neoplasia in the United States

Speaker(s)

Sharma P1, Falk GW2, Bhor M3, Ozbay AB3, Latremouille-Viau D4, Guérin A4, Shi S4, Elvekrog MM3, Limburg P5
1University of Kansas School of Medicine, Kansas City, MO, USA, 2University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, 3Exact Sciences, Madison, WI, USA, 4Analysis Group, Inc., Montreal, QC, Canada, 5Mayo Clinic, Rochester, MN, USA

Presentation Documents

Objectives: Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and esophageal neoplasia (EN). The objective was to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and EN in the US.

Methods: Using diagnosis codes in medical claims, adult patients with GERD, non-dysplastic BE (NDBE), and EN, including indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade dysplasia (HGD), or esophageal adenocarcinoma (EAC), were identified from the IBM Truven Health MarketScan databases (Q1/2015-Q4/2019) and categorized into the corresponding mutually exclusive cohorts based on the most advanced stage from GERD to EAC. Disease-related HRU and costs (2020 USD) were described for each cohort.

Results: A total of 3,310,385 patients were categorized into the GERD, 172,481 into NDBE, 11,516 into IND, 4,332 into LGD, 1,549 into HGD, and 11,676 into the EAC cohort. By cohort, mean age (year) and proportion of female were: 51.02 and 59.58% (GERD), 57.05 and 43.90% (NDBE), 58.07 and 41.21% (IND), 60.12 and 33.10% (LGD), 61.29 and 23.18% (HGD), and 62.79 and 25.15% (EAC). Disease-related annual mean number inpatient admissions, office visits, and emergency room visits by cohort were: 0.09, 1.45, and 0.19 for GERD; 0.08, 1.55, and 0.10 for NDBE; 0.10, 1.92, and 0.13 for IND; 0.09, 2.05, and 0.10 for LGD; 0.12, 2.16, and 0.14 for HGD; and 1.43, 6.27, and 0.87 for EAC. Disease-related annual mean total healthcare costs by cohort were: $6,955 for GERD, $8,755 for NDBE, $9,675 for IND, $12,241 for LGD, $24,239 for HGD, and $146,319 for EAC.

Conclusions: Patients with GERD, BE, and EN had important HRU and costs, including inpatient admissions and office visits. As patients progressed from GERD to BE to EAC, there were substantially higher disease-related resource utilization and associated costs.

Code

EE61

Topic

Economic Evaluation, Study Approaches

Disease

Gastrointestinal Disorders, Oncology